Why Is Radiopharm Theranostics Stock (RADX) Up Today?
I'm PortAI, I can summarize articles.
Radiopharm Theranostics (RADX) stock surged 292.72% in pre-market trading after announcing positive results from its Phase 2b clinical imaging trial of RAD 101 for brain metastases. The trial showed 92% concordance with MRI, indicating significant tumor uptake. CEO Riccardo Canevari highlighted RAD 101's potential to transform patient management and its estimated $500 million annual U.S. market opportunity. The stock saw heavy trading, with over 5 million shares traded compared to a daily average of 16,000 units.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments